Supporting Information

Synthesis and bioactive evaluation of N-((1-methyl-1H-indol-3-yl)methyl)-N-(3,4,5-trimethoxyphenyl)acetamide derivatives as agents for inhibiting tubulin polymerization

MS, ^{1}H NMR and ^{13}C NMR spectrum of Compounds 7a-7r

7a：






R-Indole-Pyrazole.1.fid
7.53
7.52
7.50
7.49
7.35
7.35
7.35
7.34
7.34
7.33
7.30
7.28 CDCl3
7.28
7.22
7.22
7.21
7.20
7.20
7.19
7.19
7.06
7.06
7.05
7.05
7.04
7.03
7.03
7.03
6.32
6.31
6.31
6.23
5.02
4.73
3.87
3.73
3.62
0.91
0.92
0.99
1.20
1.01
1.05
0.94
0.95
1.99
1.95
2.02
3.06
2.98
6.01
f1 (ppm)


R-Indole-Pyrazole.2.fid
166.074
153.670
139.644
138.109
136.725
136.307
130.919
129.955
127.485
121.744
119.559
119.324
110.147
109.175
106.075
105.983
77.360 CDCl3
77.105 CDCl3
76.851 CDCl3
61.006
56.096
53.593
44.661
32.716
f1 (ppm)

7b：




7 #21 RT: 0.21 AV: 1 NL: 6.54E7
T: FTMS + c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
449.2179
451.2225
436.1970
447.2025
465.2129
481.2076
483.2141
396.4539
461.2180
479.1916
505.2809
528.6595


RN-Indole-Pyrazole-4-CH3.1.fid
CDCl3
7.35
7.34
7.33
7.30
7.28
7.25
7.22
7.21
7.20
7.19
7.06
7.05
7.03
6.22
5.01
4.65
3.87
3.74
3.62
2.10
1.09
0.90
2.04
0.95
1.05
0.87
1.10
1.97
1.96
1.97
3.07
3.06
5.98
3.00
f1 (ppm)


RN-Indole-Pyrazole-4-CH3.2.fid
166.32
153.65
140.19
138.08
136.71
136.37
129.96
129.64
127.49
121.72
119.58
119.30
116.52
110.19
109.15
105.97
77.30 CDCl3
77.05 CDCl3
76.80 CDCl3
61.01
56.08
53.58
44.66
32.71
8.98
f1 (ppm)

7c：


O
O
N
N
N
N
O
O
O


8 #21 RT: 0.21 AV: 1 NL: 4.22E7
T: FTMS + c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
465.2129
497.2025
481.2076
469.2076
463.1974
479.2287
477.2126
399.1535
435.2022
445.1194
461.1823
512.1774
521.2756


RN-Indole-Pyrazole-4-OCH3.1.fid
7.36
7.36
7.35
7.34
7.34
7.34
7.29
7.29
7.28 CDCl3
7.28
7.28
7.25
7.24
7.22
7.22
7.20
7.20
7.20
7.19
7.19
7.17
7.17
7.06
7.05
7.05
7.04
7.03
7.03
7.02
6.20
5.01
4.61
3.86
3.75
3.73
3.60
0.99
1.31
0.92
1.04
0.92
1.02
0.99
1.88
1.92
1.93
2.98
3.00
3.02
6.08
f1 (ppm)


RN-Indole-Pyrazole-4-OCH3.2.fid
166.15
153.65
147.09
138.10
136.73
136.23
129.92
127.46
127.34
121.75
119.55
119.33
115.40
110.13
109.18
105.94
77.36 CDCl3
77.11 CDCl3
76.85 CDCl3
60.99
58.75
56.07
54.35
44.61
32.71
f1 (ppm)

7d：


Cl
O
N
N
N
N
O
O
O


12 #12 RT: 0.12 AV: 1 NL: 1.05E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
467.1487
470.1487
478.1725
463.1987
481.1629
453.1332
390.0971
398.1467
424.0573
434.1816
500.1460
513.1540
522.1274
537.1097
567.1311
Relative Abundance
m/z


RN-Indole-Pyrazole-4-Cl.1.fid
CDCl3
7.50
7.43
7.34
7.34
7.34
7.33
7.32
7.30
7.29
7.28
7.23
7.23
7.22
7.21
7.21
7.20
7.20
7.07
7.07
7.06
7.06
7.05
7.04
7.04
7.02
6.21
5.01
4.67
3.87
3.74
3.62
0.92
0.87
1.05
0.96
1.04
1.13
1.02
1.99
2.02
2.02
3.03
3.03
5.90
f1 (ppm)


RN-Indole-Pyrazole-4-Cl.2.fid
165.46
153.73
138.22
138.08
136.74
136.05
129.94
128.98
127.43
121.81
119.50
119.39
110.43
109.99
109.21
105.90
77.31 CDCl3
77.06 CDCl3
76.81 CDCl3
61.03
56.10
54.23
44.75
32.73
f1 (ppm)

7e：


Br
O
N
N
N
O
O
O


9 #20 RT: 0.20 AV: 1 NL: 9.67E7
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
511.0980
513.0958
512.1013
514.0992
515.1021
505.2088
509.0831
510.0900
515.9702
517.9695
525.1119
527.1111


RN-4Br.2.fid
165.44
153.73
140.19
138.22
136.74
136.05
131.12
129.94
127.43
121.81
119.50
119.39
109.98
109.21
105.89
93.60
77.29 CDCl3
77.03 CDCl3
76.78 CDCl3
61.03
56.10
54.15
44.77
32.74
f1 (ppm)


RN-4Br.1.fid
7.53
7.47
7.34
7.34
7.34
7.33
7.32
7.32
7.31
7.31
7.30
7.29
7.29
7.28 CDCl3
7.23
7.22
7.22
7.21
7.07
7.07
7.06
7.06
7.06
7.04
7.02
6.20
5.01
4.89
3.87
3.74
3.62
0.94
0.96
1.01
0.99
1.05
1.03
0.88
1.98
1.97
1.97
3.07
3.07
6.06
f1 (ppm)

7f：




6 #15 RT: 0.15 AV: 1 NL: 1.54E7
T: FTMS + c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
507.2233
506.2150
509.2399
521.2387
523.2180
505.2072
539.2127
551.2601
468.2284
510.2438
519.2236
524.2216
482.9436
495.3437
532.3727
540.2160
545.1019


RN-Indole-Pyrazole-4-C00C2CH5c4.fid
f1 (ppm)


RN-Indole-Pyrazole-4-C00C2CH5.2.fid
165.16
162.89
153.75
141.21
138.24
136.74
135.98
134.58
129.93
127.41
121.81
119.47
119.39
115.72
109.93
109.22
105.90
77.38 CDCl3
77.12 CDCl3
76.87 CDCl3
61.00
60.13
56.10
53.89
44.77
32.72
14.41
f1 (ppm)

7g：




11 #12 RT: 0.12 AV: 1 NL: 2.53E9
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
478.1726
481.1811
392.1584
419.1714
433.1878
448.1625
462.1777
492.1888
511.1696
524.1779
Relative Abundance
m/z


RN-Indole-Pyrazole-4-N02.1.fid
8.29
8.05
7.34
7.34
7.32
7.32
7.30
7.29
7.28 CDCl3
7.22
7.22
7.21
7.21
7.21
7.19
7.19
7.07
7.06
7.05
7.05
7.05
7.04
7.03
6.99
6.24
5.02
4.74
3.87
3.73
3.63
0.98
0.94
0.97
0.92
1.04
1.04
1.00
2.01
1.99
2.00
3.05
3.04
6.03
f1 (ppm)


RN-Indole-Pyrazole-4-N02.2.fid
164.30
153.86
138.41
136.78
136.20
135.74
135.59
130.76
129.93
127.35
121.90
119.45
119.39
109.69
109.32
105.88
77.40 CDCl3
77.15 CDCl3
76.89 CDCl3
61.03
56.16
54.47
44.89
32.74
f1 (ppm)

7h：




16 #20 RT: 0.20 AV: 1 NL: 3.19E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
447.2032
450.2126
444.1782
339.1706
368.1367
379.1654
397.1765
411.1556
433.1875
461.1828
483.1797
499.1743
515.1696
525.1857
547.0734
605.2963


RN-5-CH3-Indole-Pyrazole.1.fid
CDCl3
7.52
7.52
7.49
7.49
7.28
7.18
7.16
7.07
7.07
7.07
7.03
7.03
7.02
7.01
6.98
6.31
6.31
6.30
6.25
4.98
4.74
3.87
3.69
3.62
2.38
0.89
0.90
1.01
1.00
1.00
0.97
1.01
2.01
2.00
2.01
3.05
3.07
6.05
3.04
f1 (ppm)


RN-5-CH3-Indole-Pyrazole.2.fid
166.02
153.63
139.62
138.09
136.41
135.19
130.92
130.07
128.44
127.68
123.32
119.19
109.55
108.91
106.09
106.05
77.42 CDCl3
77.16 CDCl3
76.91 CDCl3
61.00
56.06
53.59
44.72
32.72
21.41
f1 (ppm)

7i：




15 #20 RT: 0.20 AV: 1 NL: 5.50E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
463.1982
466.2068
460.1754
473.2810
499.1746
502.1752
495.1875
355.1656
369.1455
393.1452
413.1711
433.1510
449.1824
531.1644
549.0730
Relative Abundance
m/z


RN-5-OCH3-indole-Pyrazole.1.fid
7.51
7.51
7.48
7.48
7.28 CDCl3
7.17
7.16
6.97
6.86
6.86
6.84
6.78
6.33
6.30
6.30
6.24
4.98
4.73
3.85
3.72
3.69
3.63
0.92
0.94
1.05
1.01
1.04
1.03
1.02
2.05
2.04
2.05
3.03
3.04
2.93
5.84
f1 (ppm)


RN-5-OCH3-indole-Pyrazole.2.fid
166.04
154.05
153.65
139.62
138.07
136.31
132.07
130.89
130.38
127.78
112.28
110.02
109.80
106.05
100.99
77.36 CDCl3
77.10 CDCl3
76.85 CDCl3
60.94
56.09
55.69
53.56
44.73
32.86
f1 (ppm)

7j：


Cl
O
N
N
N
N
O
O
O


13 #12 RT: 0.12 AV: 1 NL: 2.30E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
467.1485
470.1485
453.1328
456.1329
388.0833
399.1110
414.0977
423.1223
431.1008
447.1355
478.1721
494.1597
500.1458
513.1537
527.1694
543.1656


RN-5-Cl-indole-Pyrazole.1.fid
CDCl3
7.51
7.51
7.47
7.46
7.28
7.20
7.20
7.19
7.18
7.14
7.13
7.12
7.10
6.30
6.29
6.29
6.26
4.93
4.73
3.88
3.71
3.66
0.95
0.97
0.99
1.02
1.09
0.98
0.97
1.99
2.04
2.04
2.92
3.03
5.98
f1 (ppm)


RN-5-Cl-indole-Pyrazole.2.fid
166.16
153.82
139.69
138.35
136.38
135.08
131.45
130.92
128.46
125.18
121.96
118.93
110.35
109.95
106.07
105.96
77.39 CDCl3
77.13 CDCl3
76.88 CDCl3
61.08
56.16
53.54
44.67
32.92
f1 (ppm)

7k：


Br
O
N
N
N
N
O
O
O


14 #20 RT: 0.20 AV: 1 NL: 2.03E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
511.0979
513.0958
512.1013
514.0991
515.1021
509.0821
510.0889
510.7782
511.4092
512.7760
513.4080
516.1041
Relative Abundance
m/z


RN-5-Br-indole-Pyrazole.1.fid
7.51
7.51
7.46
7.46
7.34
7.33
7.28 CDCl3
7.26
7.26
7.25
7.24
7.15
7.13
7.09
6.30
6.29
6.29
6.26
4.92
4.72
3.89
3.70
3.67
0.96
0.98
0.99
1.03
1.02
0.99
1.03
1.95
1.98
1.97
2.98
3.07
5.91
f1 (ppm)


RN-5-Br-indole-Pyrazole.2.fid
166.17
153.82
139.70
138.35
136.40
135.32
131.33
130.92
129.12
124.50
122.03
112.70
110.81
109.90
106.08
105.94
77.39 CDCl3
77.14 CDCl3
76.89 CDCl3
61.12
56.18
53.53
44.69
32.91
f1 (ppm)

7l：


O
N
N
N
O
O
O


17 #20 RT: 0.20 AV: 1 NL: 1.03E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
447.2033
450.2124
444.1786
339.1707
364.3581
379.1654
397.1765
411.1562
433.1877
463.1987
483.1797
503.1239
515.1700
549.0721
604.2921
Relative Abundance
m/z


7.53
7.52
7.50
7.49
7.26
7.24
7.08
6.92
6.90
6.89
6.88
6.87
6.32
6.31
6.31
6.23
4.99
4.73
3.87
3.69
3.63
2.48
0.95
0.94
1.01
0.99
1.02
1.02
0.94
1.93
1.95
1.98
3.01
3.08
6.10
3.06
f1 (ppm)


RN-6-CH3-Indole-Pyrazole q.2.fid
166.02
153.64
139.62
138.08
137.18
136.32
131.56
130.91
129.30
125.35
121.09
119.32
110.00
109.12
108.06
106.00
77.38 CDCl3
77.12 CDCl3
76.87 CDCl3
61.00
56.10
53.60
44.72
32.61
21.83
f1 (ppm)

7m：


O
O
N
N
N
O
O
O


20 #18 RT: 0.19 AV: 1 NL: 9.73E4
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
463.19812
464.20193
462.17764
464.15662
465.20343
466.13992
Relative Abundance
m/z


RN-6-OCH3-Indole-Pyrazole.1.fid
7.49
7.49
7.46
7.46
7.28 CDCl3
7.23
7.21
6.85
6.71
6.71
6.71
6.70
6.69
6.69
6.27
6.27
6.27
6.22
4.95
4.71
3.84
3.84
3.63
3.61
0.94
0.99
0.99
0.98
2.01
1.07
2.01
2.02
2.01
2.72
3.12
2.88
6.17
f1 (ppm)


RN-6-OCH3-Indole-Pyrazole.2.fid
166.02
156.42
153.62
139.57
138.05
137.51
136.24
130.93
128.74
121.81
120.32
110.16
109.17
106.01
105.96
92.72
77.52 CDCl3
77.27 CDCl3
77.01 CDCl3
60.96
56.10
55.69
53.57
44.66
32.66
f1 (ppm)

7n：


Cl
O
N
N
N
N
O
O
O


19 #20 RT: 0.20 AV: 1 NL: 2.49E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
467.1483
469.1447
470.1485
471.1513
453.1327
455.1296
465.1317
473.2818
477.0791
484.1480
488.1001
494.1592


RN-6-Cl-indole-Pyrazole.1.fid
7.52
7.52
7.47
7.47
7.28 CDCl3
7.27
7.27
7.27
7.25
7.01
7.01
7.00
6.99
6.31
6.30
6.30
6.21
4.96
4.72
3.86
3.68
3.64
0.96
0.98
0.90
1.01
0.89
1.08
1.01
2.05
2.10
2.11
2.97
3.03
5.92
f1 (ppm)


RN-6-Cl-indole-Pyrazole.2.fid
166.14
153.75
139.70
138.19
137.13
136.16
130.89
130.57
127.85
126.00
120.57
119.99
110.52
109.26
108.10
105.85
77.36 CDCl3
77.11 CDCl3
76.85 CDCl3
61.01
56.14
53.54
44.49
32.81
f1 (ppm)

7o：


Br
O
N
N
N
N
O
O
O


18 #16 RT: 0.16 AV: 1 NL: 8.84E7
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
511.0977
513.0956
512.1011
514.0992
503.1253
504.1284
505.1226
506.1262
502.1432
515.1009
Relative Abundance
m/z


RN-6-Br-Indole-Pyrazole.1.fid
7.51
7.51
7.46
7.46
7.43
7.43
7.28 CDCl3
7.22
7.20
7.13
7.13
7.11
7.11
6.97
6.30
6.29
6.29
6.20
4.95
4.71
3.86
3.67
3.63
0.98
0.96
0.96
1.05
1.02
0.92
1.11
2.11
2.16
2.13
2.83
2.98
5.79
f1 (ppm)


RN-6-Br-Indole-Pyrazole.2.fid
166.15
153.74
139.69
138.18
137.53
136.14
130.91
130.51
126.31
122.54
120.93
115.44
112.28
110.55
106.09
105.85
77.41 CDCl3
77.15 CDCl3
76.90 CDCl3
61.01
56.15
53.53
44.46
32.81
f1 (ppm)

7p：




3 #22 RT: 0.22 AV: 1 NL: 4.66E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
434.1830
435.1863
436.1893
404.1371
420.1673
433.1751
437.1920
448.1989
Relative Abundance
m/z


RN-indole-1, 2, 4-Triazole.1.fid
CDCl3
8.21
7.93
7.33
7.31
7.29
7.28
7.27
7.22
7.21
7.20
7.20
7.20
7.18
7.18
7.06
7.06
7.04
7.04
7.04
7.03
7.03
6.99
6.22
5.01
4.76
3.86
3.72
3.61
0.97
0.95
1.00
1.25
1.00
1.00
0.98
1.99
1.98
1.99
2.95
2.99
5.96
f1 (ppm)


RN-indole-1, 2, 4-Triazole.2.fid
164.61
153.79
151.65
144.77
138.31
136.75
135.85
129.90
127.39
121.85
119.42
109.82
109.26
105.89
77.39 CDCl3
77.13 CDCl3
76.88 CDCl3
61.01
56.13
51.03
44.78
32.73
f1 (ppm)

7q：


O
N
N
N
N
O
O
O


1 #20 RT: 0.20 AV: 1 NL: 3.43E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
434.1830
435.1862
436.1891
420.1673
422.1738
433.1751
437.1919
441.1212
448.1625
450.1776
455.1367
461.1937
Relative Abundance
m/z


RN-Indole-1-(1, 2, 3-Triazole).1.fid
7.81
7.81
7.74
7.74
7.34
7.34
7.34
7.33
7.33
7.32
7.31
7.31
7.30
7.29
7.29
7.29
7.28 CDCl3
7.23
7.23
7.22
7.21
7.21
7.20
7.20
7.07
7.07
7.06
7.06
7.05
7.04
7.04
6.99
6.23
5.02
4.99
3.88
3.74
3.63
0.91
0.89
1.01
1.03
1.02
1.05
0.97
2.00
1.96
1.88
3.11
3.05
6.13
f1 (ppm)


RN-Indole-1-(1, 2, 3-Triazole).2.fid
164.43
153.83
138.36
136.76
135.78
133.83
129.89
127.37
125.31
121.89
119.46
119.41
109.80
109.28
105.90
77.33 CDCl3
77.08 CDCl3
76.83 CDCl3
61.03
56.15
51.18
44.76
32.75
f1 (ppm)

7r：




2 #16 RT: 0.16 AV: 1 NL: 2.51E8
T: FTMS - c APCI corona Full ms [60.0000-900.0000]
Relative Abundance
m/z
434.1830
435.1863
436.1892
437.1923
409.3108
415.1064
420.1674
427.1274
433.1746
442.2410
446.2352
452.1567
457.2875
466.1726
468.1778
470.1594
472.1557
475.2888
479.2239


R-Indole-2-(1,2,3-Triazole)-3.fid
CDCl3
7.69
7.33
7.32
7.32
7.31
7.31
7.31
7.30
7.30
7.28
7.28
7.28
7.22
7.22
7.21
7.20
7.20
7.19
7.19
7.06
7.06
7.05
7.04
7.04
7.03
7.03
6.27
5.07
5.02
3.87
3.73
3.62
1.77
0.98
1.26
1.07
2.07
1.94
1.96
1.97
2.99
3.00
6.00
f1 (ppm)



Molecular docking study of 7a-7r

Compounds	S-score（kcal/mol）	Interactions	Amino acids involved	Atoms/fragment involved in ligand
7a	-5.90	-	-	-
7b	-6.08	-	-	-
7c	-6.74	H-acceptor, pi-pi	ARG 264, HIS 192	N 29, 6-ring
7d	-7.16	pi-H, pi-cation, pi-pi	GLU 196 ARG 264 HIS 192	5-ring, 6-ring, 6-ring
7e	-6.64	H-donor	GLU 155	Br 33
7f	-7.36	H-donor, H-acceptor, pi-H	GLU 196, LYS 104, THR 193	C 16, O 34, 5-ring
7g	-6.22	pi-H	ARG 390	5-ring
7h	-6.25	-	-	-
7i	-7.02	H-acceptor, pi-H	GLU 196, THR 193, LYS 100, HIS 192	C 27, 5-ring, 5-ring, 5-ring

7j	-6.95	pi-cation, pi-pi	ARG 264, HIS 100	5-ring, 6-ring
7k	-6.57	pi-cation, pi-pi	THR 193, ARG 264	5-ring, 6-ring
7l	-5.75	pi-H	LYS 304	5-ring
7m	-6.77	H-acceptor, pi-H, pi-cation	LYS 394, ARG 390	O 14, 5-ring
7n	-6.78	H-donor	ASP 199	Cl 33
7o	-6.53	pi-H, pi-H	GLU 196, LYS 100	5-ring, 6-ring
7p	-5.71	-	-	-
7q	-5.71	-	-	-
7r	-5.8294	-	-	-

Comp.	2D views	3D views
7a		
7b		

7c	 Glu A426 Thr A193 His A192 Asp A424 Lys B100 Lys B104 Arg A264 Glu A196 Pro A263 His A197 Leu A195	
7d	 Glu A420 Glu A423 Thr A193 His A192 Asp A424 Pro A263 Ala A427 Arg A264 His A197 Glu A196 His A268 Lys B100 Leu A195 Lys B104 Cl	
7e	 Ala 427 Glu 420 Glu 423 His 192 Asp 424 Thr 193 Br Glu 195 Glu 195 Arg 264 His 197 Pro 263 Leu 195	

7f		
7g		
7h		
7i		

7j		
7k		
7l		
7m		

7n		
7o		
7p		

7q	 Asp A396 Asp B431 Ala B430 Leu A397 Ala A426 Arg A422 Ala A400 Arg A402 Ser A419 Tyr A399	
7r	 Ser 419 Tyr 399 Ala 400 Glu 423 Phe 395 Arg 422 Ala 426 Asp 396 Glu 429 His 393